ArticleBriefings in bioinformatics2026
PEARL: novel protein targets recommendation model via heterogeneous graph representation learning.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Peptide drug repurposing depends on identifying likely protein targets for a query peptide across a large candidate space, yet most existing peptide-protein interaction models are optimized for isolated pairwise classification rather than target prioritization. Here, we present PEARL, a recommendation-oriented heterogeneous graph learning framework for peptide target recommendation. PEARL represents peptides and proteins as distinct node types connected by known peptide-protein associations and multi-view peptide similarity, and combines graph-based representation learning with similarity-aware score refinement to rank candidate targets for a query peptide. On the UMPPI benchmark, PEARL achieved mean area under the receiver operating characteristic curve (AUC), area under the precision-recall curve (AUPR), and Matthews correlation coefficient values of 0.868, 0.855, and 0.571 in five-fold cross-validation, outperforming the strongest baseline, HGT-PepPI, by 4.4, 4.8, and 7.0 percentage points, respectively. Under clustered cold-start evaluation, PEARL delivered the best overall AUC across the novel-protein, novel-peptide, and novel-pair settings, indicating robust generalization under increasing sequence dissimilarity. PEARL also remained the top performer on two independent test sets, reaching an AUC of 0.863 on Test167 and 0.871 on Test1440. Additional analyses showed that PEARL can be effectively calibrated and that its learned latent space groups functionally related targets beyond simple sequence identity. In a case study of the unseen therapeutic peptide CIGB-814, PEARL ranked SPSB2 as the top candidate target. Docking and molecular dynamics simulations supported a stable binding mode, and surface plasmon resonance further confirmed direct binding with an apparent KD of 5.538 μM. Together, these results support PEARL as a scalable computational framework for peptide target recommendation and peptide drug repurposing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.